...
首页> 外文期刊>Journal of Surgical Oncology >BRCA1 expression in leukoplakia and carcinoma of the tongue.
【24h】

BRCA1 expression in leukoplakia and carcinoma of the tongue.

机译:BRCA1在白斑和舌癌中的表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVES: Expression of BRCA1 was examined in patients with leukoplakia and carcinoma of the tongue. Its prognostic value was evaluated in patients with tongue cancer. METHODS: Expression of BRCA1 was studied by immunohistochemical localization. Cytoplasmic staining of BRCA1 was observed in both leukoplakia and carcinoma of the tongue. RESULTS: In leukoplakia, 61% and 39% of the patients expressed BRCA1 expression with a staining intensity of 1+ and 2+, respectively. In patients with hyperplasia (67%), BRCA1 expression with a staining intensity of 1+ was 67%; BRCA1 expression with a staining intensity of 2+ was 33%. In patients with dysplasia (33%; mild and moderate), BRCA1 expression with a staining intensity of 1+ and 2+ was 50% each. In carcinoma of the tongue, only 34% of the patients showed BRCA1 expression. In this group, 33% of the tumors exhibited 1+ staining, and only 1% of the tumors expressed 2+ staining. Moreover, BRCA1 expression with a staining intensity of 2+ was significantly higher in patients with dysplasia (50%) than in those with hyperplasia (33%), followed by patients with squamous cell carcinoma of the tongue (1%). The percentage positivity of BRCA1 expression in tongue cancer patients was significantly lower (34%), as compared with patients with leukoplakia (100%; P = 0.000001). A significant positive correlation was noted between BRCA1 and c-myc (P = 0.012). Univariate survival analysis by log-rank test and multivariate survival analysis by Cox regression showed that BRCA1 expression was the most significant prognostic factor predicting relapse-free survival of early-stage patients. CONCLUSIONS: Subcellular localization of the BRCA1 gene product provided evidence of its involvement in the pathogenesis of tongue tumors.
机译:背景与目的:检测白斑和舌癌患者BRCA1的表达。在舌癌患者中评估其预后价值。方法:通过免疫组织化学定位研究BRCA1的表达。在白斑和舌癌中均观察到BRCA1的细胞质染色。结果:在白斑患者中,分别有61%和39%的患者表达BRCA1表达,染色强度分别为1+和2+。在增生患者(67%)中,染色强度为1+的BRCA1表达为67%。染色强度为2+的BRCA1表达为33%。在发育异常的患者中(33%;轻度和中度),染色强度分别为1+和2+的BRCA1表达各为50%。在舌癌中,只有34%的患者显示BRCA1表达。在这一组中,33%的肿瘤表现为1+染色,只有1%的肿瘤表现为2+染色。此外,异型增生患者(50%)的染色强度为2+的BRCA1表达显着高于增生患者(33%),其次是舌鳞状细胞癌患者(1%)。与白斑患者(100%; P = 0.000001)相比,舌癌患者中BRCA1表达的阳性率显着降低(34%)。注意到BRCA1和c-myc之间存在显着的正相关(P = 0.012)。对数秩检验的单变量生存分析和Cox回归的多变量生存分析表明,BRCA1表达是预测早期患者无复发生存的最重要预后因素。结论:BRCA1基因产物的亚细胞定位提供了其参与舌癌发病机制的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号